Outset Medical FY 2023: revenue $130.4M, up 13%; diluted EPS −$3.48
- Form
- 10-K
- Filed
- Period
- Importance
- Notable
- Accession
- 0000950170-24-018093
Key figures from this report
These are the numbers Outset Medical reported for the year ended Dec 31, 2023, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.
- Revenue$130.4M+13% from $115.4M in FY 202210-K income statement, on EDGAR
- Net income−$172.8MAgainst −$163.0M in FY 202210-K income statement, on EDGAR
- Diluted EPS−$3.48Against −$3.38 in FY 202210-K income statement, on EDGAR
- Cash and cash equivalents$68.5M−6% from $73.2M in FY 2022Cash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
- Cash from operations−$131.4MAgainst −$145.7M in FY 202210-K cash flow statement, on EDGAR
Similar companies
Same SIC code (3845) and public float $300M to $2B, nearest public float first, as each company reports it on its annual report cover.
- Ceribell CBLL public float $417M, Jun 30, 2025
- Axogen AXGN public float $431M, Jun 30, 2025
- Biolife Solutions BLFS public float $845M, Jun 30, 2025
- CONMED CNMD public float $1.2B, Jun 30, 2025
